Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Nezam Hassan Afdhal, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01AT003571 (AFDHAL, NEZAM HASSAN) Aug 15, 2006 - Jul 31, 2011
    Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease
    Role: Principal Investigator
  2. U19AI066313 (SCHUPPAN, DETLEF) Jun 30, 2005 - Nov 28, 2010
    Determinants of Liver Injury in Chronic Hepatitis C Virus Infection
    Role: Co-Principal Investigator
  3. R21CA108303 (AFDHAL, NEZAM HASSAN) Sep 25, 2003 - Aug 31, 2005
    Proteomics and Biomarkers for Hepatocellular Cancer
    Role: Principal Investigator
  4. U01DK060340 (AFDHAL, NEZAM HASSAN) Aug 21, 2001 - Jun 30, 2006
    Antiviral Therapy in African Americans with HCV
    Role: Principal Investigator
  5. R01DK045936 (AFDHAL, NEZAM HASSAN) Jul 15, 1993 - May 31, 2003
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Giannini EG, Kano T, Ochiai T, Bentley R, Shrestha P, Afdhal N. Bleeding events in lusutrombopag-treated thrombocytopenic patients. Eur J Clin Invest. 2021 Feb 01; e13503. PMID: 33523482.
    Citations:    Fields:    
  2. Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, Abutidze A, Sharvadze L, Kerashvili V, Butsashvili M, Metreveli D, Gvinjilia L, Shadaker S, Nasrullah M, Adamia E, Zeuzem S, Afdhal N, Arora S, Thornton K, Skaggs B, Kuchuloria T, Lagvilava M, Sergeenko D, Averhoff F. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018. Clin Infect Dis. 2020 08 22; 71(5):1263-1268. PMID: 31563938.
    Citations: 7     Fields:    Translation:HumansCells
  3. Ezaz G, Trivedi HD, Connelly MA, Filozof C, Howard K, L Parrish M, Kim M, Herman MA, Nasser I, Afdhal NH, Jiang ZG, Lai M. Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD. Hepatol Commun. 2020 May; 4(5):670-680. PMID: 32363318.
    Citations: 2     
  4. Navarro VJ, Belle SH, D'Amato M, Afdhal N, Brunt EM, Fried MW, Rajender Reddy K, Wahed AS, Harrison S. Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One. 2019; 14(10):e0223915. PMID: 31600349.
    Citations:    Fields:    
  5. Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology. 2019 11; 70(5):1521-1530. PMID: 31271665.
    Citations: 20     Fields:    Translation:Humans
  6. Sasaki R, Shiino C, Imawari M, Bentley R, Cai B, Yoshida M, Afdhal N. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Hepatol Res. 2019 Oct; 49(10):1169-1181. PMID: 31228221.
    Citations: 3     
  7. Tsai N, Bacon B, Curry M, Flamm SL, Milligan S, Wick N, Younossi Z, Afdhal N. Changing demographics among populations prescribed HCV treatment, 2013-2017. Am J Manag Care. 2019 07; 25(7):319-323. PMID: 31318504.
    Citations: 1     Fields:    Translation:Humans
  8. Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019 12; 70(6):1913-1927. PMID: 30993748.
    Citations: 28     Fields:    Translation:Humans
  9. Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019 06; 48(2):281-289. PMID: 31046975.
    Citations: 4     Fields:    Translation:Humans
  10. Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019 10; 70(4):1336-1348. PMID: 30762895.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  11. Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology. 2019 02; 69(2):684-698. PMID: 30153359.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  12. Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018 Dec; 2(12):1467-1478. PMID: 30556036.
    Citations: 5     
  13. Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141. PMID: 30291868.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  14. Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol. 2018 12; 69(6):1365-1370. PMID: 30144554.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  15. Leahy J, O'Leary A, Afdhal N, Gray E, Milligan S, Wehmeyer MH, Walsh C. The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection. Res Synth Methods. 2018 Sep; 9(3):441-469. PMID: 29923679.
    Citations: 4     Fields:    Translation:Humans
  16. Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018 10; 155(4):1140-1153. PMID: 29990488.
    Citations: 43     Fields:    Translation:HumansCTClinical Trials
  17. Babusis D, Curry MP, Kirby B, Park Y, Murakami E, Wang T, Mathias A, Afdhal N, McHutchison JG, Ray AS. Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. Antimicrob Agents Chemother. 2018 05; 62(5). PMID: 29439971.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  18. Flamm SL, Bacon B, Curry MP, Milligan S, Nwankwo CU, Tsai N, Younossi Z, Afdhal N. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther. 2018 06; 47(11):1511-1522. PMID: 29665097.
    Citations: 5     Fields:    Translation:Humans
  19. El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, McHutchison J, Brainard DM, Terrault N, Curry MP. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8. PMID: 29535028.
    Citations: 13     Fields:    Translation:HumansCells
  20. Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis. 2018 Feb; 5(2):ofy001. PMID: 29450210.
    Citations: 6     
  21. Loomba R, Gindin Y, Jiang Z, Lawitz E, Caldwell S, Djedjos CS, Xu R, Chung C, Myers RP, Subramanian GM, Goodman Z, Charlton M, Afdhal NH, Diehl AM. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2). PMID: 29367468.
    Citations: 8     Fields:    Translation:HumansCells
  22. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559. PMID: 28892558.
    Citations: 109     Fields:    Translation:HumansCTClinical Trials
  23. Jiang ZG, Sandhu B, Feldbrügge L, Yee EU, Csizmadia E, Mitsuhashi S, Huang J, Afdhal NH, Robson SC, Lai M. Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018 07; 16(7):1170-1172. PMID: 29170098.
    Citations: 2     Fields:    Translation:HumansCells
  24. Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, Lee Y, Milligan S, Tsai N, Younossi Z, Afdhal NH. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017 09; 46(5):540-548. PMID: 28691377.
    Citations: 13     Fields:    Translation:HumansCells
  25. Jones M, Cunningham ME, Wing P, DeSilva S, Challa R, Sheri A, Padmanabhan S, Iyer RP, Korba BE, Afdhal N, Foster GR. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 09; 89(9):1620-1628. PMID: 28303593.
    Citations: 7     Fields:    Translation:HumansCells
  26. Tapper EB, Afdhal NH, Curry MP. Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation. 2017 05; 101(5):933-937. PMID: 28437385.
    Citations: 7     Fields:    Translation:Humans
  27. Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, Curry MP, Afdhal NH. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2017 05; 101(5):987-995. PMID: 27495755.
    Citations: 4     Fields:    Translation:Humans